Clinical TrialEsketamine

ESKALE: descriptive study of patients with treatment-resistant depression treated with esketamine, within the framework of the cohort ATU, the post-ATU program or the post-marketing period

Ask Blossom about this trial
Target Enrollment
Not specified
Study Type
interventional
Design
Randomized

Study Protocol

Preparation

sessions

Dosing

sessions

Integration

sessions

Therapeutic Protocol

Manualized psychotherapy included

Study Arms & Interventions

Esketamine

experimental

Intranasal esketamine spray, alone or combined with oral antidepressants, during a 4-week induction period.

Interventions

  • Esketamine
    via intranasal• null

    Used in a real-world, non-interventional study (ESKALE) for patients with treatment-resistant depression.

Study Details

  • Type
    interventional
  • Design
    Randomized
  • Compound
    Esketamine

Related Publications

Open AccessindividualSecondary analysis

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study

This post-hoc analysis (n=128) of the French real-world ESKALE study found that intranasal esketamine produced a rapid and steadily increasing antidepressant response in patients with treatment-resistant depression over four weeks (response rate rising from 19% at week one to 47% at week four), and that experiencing dissociation during the first week of treatment may be an early indicator of a positive response.

Published
Journal
Journal of Psychiatric Research
Authors
Samalin, L., Rothärmel, M., Mekaoui, L., Sauvaget, A., Wicart, C., Gaudre-Wattine, E., Cohignac, V., Malatesta, A., Dupin, J.